Lv1
50 积分 2024-03-18 加入
AMG 509 (Xaluritamig), an Anti-STEAP1 XmAb 2+1 T-cell Redirecting Immune Therapy with Avidity-Dependent Activity against Prostate Cancer
1个月前
已完结
Population Pharmacokinetics of Tarlatamab, a Half-Life Extended DLL3-Directed Bispecific T-Cell Engager in Patients with Previously Treated Small Cell Lung Cancer
5个月前
已完结
Pharmacokinetics of Tarlatamab, a Delta-Like Ligand-3 (DLL3) Targeted Half-Life Extended Bispecific T-Cell Engager (BiTE®) Immunotherapy in Adult Patients with Previously Treated Small-Cell Lung Cancer: Results from DeLLphi-300, a Phase I Multiple-Dose-Escalation Study
5个月前
已完结
STEAP Proteins: Roles in disease biology and potential for therapeutic intervention
5个月前
已完结
Tumour-associated vasculature in T cell homing and immunity: opportunities for cancer therapy
1年前
已完结
皖公网安备34019202002308
